ABOUT US
IES Life Sciences, Inc. is an Innovative, Precision Diagnostics Company with patented technology that interrogates the human immune system to improve diagnosis and treatment of traditionally hard-to-diagnose diseases at their earliest stages.
Learn more about our current patented technology
TESTIMONIALS
“IES’s business model aspires to improve early, effective diagnosis for a number of medical ailments based on licensed technology from the NIH. The combination of a plausible business model and a management team with significant investment of personal commitment, financial resources, and passion seems, to me, the right combination of elements to make IES a solid investment thesis.”
- Investor
"I was afflicted and impacted by Lupus. It took over 4 years to figure out what was happening. With the IES technology, it is probable that I could have been diagnosed quickly and would have received appropriate treatment much sooner. Additionally, I would not have wasted time going from doctor to doctor trying to determine what was wrong. Early diagnosis is beneficial to all concerned. "
- Patient
OUR RESEARCH
OUR FIRST TARGET: LUPUS


SLE accounts for more than 77,000 annual US hospital admissions
Average stay of 10 days

INITIAL DIAGNOSIS
Given the large patient population, the difficulty in diagnosis and the substantial benefits of early diagnosis, IES has chosen to initially focus on Lupus SLE. Because the symptoms of Lupus masquerade as a number of other diseases, a definitive diagnosis is extremely challenging, lengthy and costly. Misdiagnosis and late diagnosis are two fundamental reasons why Lupus is so damaging. It can take four to six years or more for a definitive diagnosis. While early diagnosis has been proven to dramatically increase patient outcomes, delayed diagnosis compromises organs resulting in serious and often life-threatening complications. An early stage diagnostic blood test will dramatically reduce the time between initial symptoms and diagnosis, resulting in dramatically better patient outcomes and substantial healthcare savings.
THE BENEFITS OF THE IES TEST DO NOT STOP
AT INITIAL DIAGNOSIS.
ADDITIONAL USES INCLUDE:
-
Defining Treatment - As expensive, powerful new therapeutics are developed to help treat Lupus, the IES test will be used to stratify patients, identifying the subset of Lupus patients that will actually benefit from the treatment. This will prevent patients who will not benefit from receiving unnecessary and potentially dangerous treatment and will, at the same time, save payers from having to pay for an expensive * treatment that will not work on a particular patient.
-
Treatment Monitoring - Once the patient that will benefit from the drug is identified, the IES test will be used on an ongoing basis (approximately four times a year) to monitor the effectiveness of treatment and make adjustments accordingly.
* Anifrolumab, the first new Lupus SLE therapeutic in years, is expected to receive FDA approval later this year and is estimated to cost $100,000 a year.
WHY LUPUS?
MANAGEMENT TEAM
KEY ADVISORY BOARD MEMBERS
CONTACT US
IES Life Sciences, Inc.
Eastern Shore Innovation Center
104 Tech Park Drive
Suite 28
Cambridge, MD 21613
Email:
Phone: (443) 267-6601